Equity Overview
Price & Market Data
Price: $2.49
Daily Change: -$0.0397 / 1.59%
Range: $2.45 - $2.49
Market Cap: $753,909,632
Volume: 2,588
Performance Metrics
1 Week: 4.12%
1 Month: -2.32%
3 Months: -28.33%
6 Months: -11.85%
1 Year: -34.63%
YTD: -13.65%
Company Details
Employees: 596
Sector: Health technology
Industry: Biotechnology
Country: Canada
Details
AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its product pipeline includes ABCL635, an antibody-drug candidate, which is in preclinical trial to treat metabolic and endocrine conditions; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in preclinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; and partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.